[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588935":3},{"organization":4,"armGroups":7,"interventions":33,"overallOfficials":66,"centralContacts":70,"locations":79,"responsibleParty":125,"collaborators":127,"id":131,"slug":132,"hasResults":133,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":133,"sex":139,"minAge":140,"maxAge":10,"enrollmentInfo":141,"targetDuration":10,"studyType":144,"phases":10,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":82,"whyStopped":10,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":160},{"fullName":5,"class":6},"University of Aberdeen","OTHER",[8,16,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants with mild small vessel disease (Fazekas score = 1)",null,"Participants with mild small vessel disease, defined by a Fazekas score of 1.",[13,14,15],"Other: Enrolment 3T MRI research scan","Other: Enrolment Field-cycling Imaging research scan","Other: Enrolment cognitive assessment interview",{"label":17,"type":10,"description":18,"interventionNames":19},"Participants with moderate small vessel disease (Fazekas score = 2)","Participants with mild small vessel disease, defined by a Fazekas score of 2.",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"Participants with severe small vessel disease (Fazekas score = 3)","Participants with mild small vessel disease, defined by a Fazekas score of 3.",[13,14,15],{"label":25,"type":10,"description":26,"interventionNames":27},"Follow up group. Participants with moderate or severe small vessel disease (Fazekas score = 2 or 3).","Participants with moderate or severe SVD (deep white matter Fazekas 2 or 3) who will undergo an extra low-field MRI scan and will have a follow up visit at 18 months.",[13,14,28,29,30,31,15,32],"Other: Enrolment ultra-low field MRI research scan","Other: Follow up 3T MRI research scan","Other: Follow up Field-cycling Imaging research scan","Other: Follow up ultra-low field MRI research scan","Other: Follow up cognitive assessment interview",[34,38,42,46,50,54,58,62],{"type":6,"name":35,"description":36,"armGroupLabels":37,"otherNames":10},"Enrolment 3T MRI research scan","Enrolment research scan performed with 3T magnetic resonance imaging scanner.",[25,9,17,21],{"type":6,"name":39,"description":40,"armGroupLabels":41,"otherNames":10},"Enrolment Field-cycling Imaging research scan","Enrolment research scan performed with Field-Cycling Imaging scanner.",[25,9,17,21],{"type":6,"name":43,"description":44,"armGroupLabels":45,"otherNames":10},"Enrolment ultra-low field MRI research scan","Enrolment research scan performed with ultra-low field MRI scanner",[25],{"type":6,"name":47,"description":48,"armGroupLabels":49,"otherNames":10},"Follow up 3T MRI research scan","Follow up research scan performed with 3T magnetic resonance imaging scanner, 18-months after baseline scans.",[25],{"type":6,"name":51,"description":52,"armGroupLabels":53,"otherNames":10},"Follow up Field-cycling Imaging research scan","Follow up research scan performed with Field-Cycling Imaging scanner, 18-months after baseline scans.",[25],{"type":6,"name":55,"description":56,"armGroupLabels":57,"otherNames":10},"Follow up ultra-low field MRI research scan","Follow up research scan performed with Ultra-low field MRI scanner, 18-months after baseline scans.",[25],{"type":6,"name":59,"description":60,"armGroupLabels":61,"otherNames":10},"Enrolment cognitive assessment interview","Enrolment interview performed to complete cognitive assessment scoring of Montreal Cognitive Assessment, EQ-5D, Trail making test, Animal naming test, controlled oral word association test, and Hopkins Verbal Learning Test.",[25,9,17,21],{"type":6,"name":63,"description":64,"armGroupLabels":65,"otherNames":10},"Follow up cognitive assessment interview","Follow up interview performed to complete cognitive assessment scoring of Montreal Cognitive Assessment, EQ-5D, Trail making test, Animal naming test, controlled oral word association test, and Hopkins Verbal Learning Test. Performed 18-months after baseline interview.",[25],[67],{"name":68,"affiliation":5,"role":69},"Mary Joan MacLeod","STUDY_CHAIR",[71,75],{"name":68,"role":72,"phone":73,"phoneExt":10,"email":74},"CONTACT","+44 1224 438352","m.j.macleod@abdn.ac.uk",{"name":76,"role":72,"phone":77,"phoneExt":10,"email":78},"Gordon D Waiter","+44 1224 438356","g.waiter@abdn.ac.uk",[80,107],{"facility":81,"status":82,"city":83,"state":10,"zip":84,"country":85,"countryCode":86,"cosmosGeoPoint":87,"geoPoint":92,"contacts":93},"Aberdeen Biomedical Imaging Centre, University of Aberdeen","RECRUITING","Aberdeen","AB24 3FX","United Kingdom","UK",{"type":88,"coordinates":89},"Point",[90,91],-2.09814,57.14369,{"lat":91,"lon":90},[94,96,99,101,103,105],{"name":95,"role":72,"phone":77,"phoneExt":10,"email":78},"Gordon Waiter, PhD",{"name":97,"role":72,"phone":98,"phoneExt":10,"email":74},"Mary Joan MacLeod, PhD","+44 1224 437842",{"name":76,"role":100,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"name":102,"role":100,"phone":10,"phoneExt":10,"email":10},"Adamu Ali-Gombe, PhD",{"name":104,"role":100,"phone":10,"phoneExt":10,"email":10},"Nicholas Senn, PhD",{"name":97,"role":106,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":108,"status":82,"city":83,"state":10,"zip":84,"country":85,"countryCode":86,"cosmosGeoPoint":109,"geoPoint":111,"contacts":112},"AMT Center, Univeristy of Aberdeen",{"type":88,"coordinates":110},[90,91],{"lat":91,"lon":90},[113,117,121,122,123,124],{"name":114,"role":72,"phone":115,"phoneExt":10,"email":116},"Mathieu Sarracanie, PhD","+44 1224 437365","mathieu.sarracanie@abdn.ac.uk",{"name":118,"role":72,"phone":119,"phoneExt":10,"email":120},"Najat Salameh, PhD","+44 1224 437360","najat.salameh@abdn.ac.uk",{"name":114,"role":100,"phone":10,"phoneExt":10,"email":10},{"name":118,"role":100,"phone":10,"phoneExt":10,"email":10},{"name":104,"role":100,"phone":10,"phoneExt":10,"email":10},{"name":97,"role":106,"phone":10,"phoneExt":10,"email":10},{"type":126,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[128],{"name":129,"class":130},"NHS Grampian","OTHER_GOV","100588935","puffins-brain-health-study-100588935",false,"NCT06947876","PUFFINS Brain Health Study","Proving the Utility of Ultra-low Field MRI for Assessing Brain Health","PUFFINS BH","Inclusion Criteria:\n\n* Adults ≥ 50 years old.\n* Subjects who do not report problems with memory.\n* Small vessel disease (Fazekas score 1 to 3).\n* Suitable body habitus.\n* Able to understand written and spoken English.\n\nExclusion Criteria:\n\n* History of major stroke (minor stroke\u002FTransient Ischaemic Attacks or lacunar stroke are acceptable).\n* Individuals unable to give informed consent.\n* Contra-indications to MRI scanning such as implantable cardiac devices.","ALL","50 Years",{"count":142,"type":143},85,"ESTIMATED","OBSERVATIONAL","Small vessel disease (SVD) is a major cause of stroke and contributor to dementia cases. As work continues to develop new treatments to address the impact of SVD, new imaging techniques are needed to identify and track the progression of brain changes that occur with SVD. Magnetic Resonance Imaging (MRI) is the gold standard to diagnose poor brain health due to small vessel disease. However, current MRI systems are expensive and complex to operate, and so access is limited.\n\nLow-field MRI technology, operating at magnetic field strengths many times lower than conventional MRI, can make brain imaging much more cost-effective and accessible. However, further work is needed to develop low-field MRI towards clinically feasible assessments of brain health. The University of Aberdeen hosts a unique network of researchers and imaging technologies that is now making it possible to test and develop different low-field MRI approaches towards solving key healthcare challenges.\n\nThe aim of this study is to evaluate the potential of two distinct approaches, field-cycling imaging (FCI) and ultra-low field MRI (ULF-MRI), to detect brain changes linked with small vessel disease. Automated methods will be developed to analyse images and extract measurements that detect and track progression of disease severity.",[147],"Cerebral Small Vessel Disease",[149,150],"Field-cycling imaging","Ultra-low field MRI","2026-05-04",{"date":153,"type":154},"2026-05-05","ACTUAL",{"date":156,"type":154},"2025-12-17",{"date":158,"type":143},"2027-05",{"name":5,"class":6},2]